Inovio Pharmaceuticals has expedited its timeline for the development of a Covid-19 vaccine candidate, INO-4800, with human clinical trials scheduled for April. The company already had a vaccine candidate in Phase II development for similar coronavirus that leads to the development of Middle East Respiratory Syndrome (MERS). Inovio leveraged itsContinue Reading